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Abstract
Background: West Nile Virus (WNV) is endemic in Israel and a significant level of antibodies is
present in the population due to natural exposure. Anecdotal cases suggested that the presence of
anti-WNV antibodies in intravenous immunoglobulin (IVIG) from Israeli donors (IVIG-IL) assisted
the recovery of patients with severe WNV infection.
Methods:  To enhance the therapeutic efficacy of IVIG-IL against WNV infection, OMRIX
Biopharmaceuticals, Israel, have developed a strategy for selection of plasma units from a 10%
fraction of Israeli blood donors with anti-WNV antibodies. Positive units were processed into
pharmaceutical grade WNV IVIG (WNIG). Following inoculation with WNV, mice received i.p.
injections of different doses (0.01–8 mg/mouse) of IVIG-IL or WNIG, according to the specific
experimental protocol.
Results: WNIG was about 10 times more potent (per gr of IgG) than was regular IVIG-IL when
tested by ELISA and neutralization assays. In a mouse lethal WNV infection model, prophylactic
treatment with WNIG was at least 5–10-fold more potent as compared to treatment with IVIG-
IL. Treatment with WNIG during active encephalitis, three or four days following WNV infection,
had a significant protective effect. WNIG was also very effective in protecting immunosuppressed
mice. Indeed, treatment of dexamethasone-immunosuppressed mice with 0.2 or 1.0 mg WNIG 4
h after virus infection, led to 100% survival.
Conclusion: IVIG produced from selected plasma donated in WNV endemic regions can be used
to produce WNV IVIG with superior activity for therapeutic and prophylactic measures.
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Background
Passive transfer of antibodies has been shown to be effec-
tive for the prevention and treatment of many infectious
diseases, including those caused by viruses [1]. Intrave-
nous human immunoglobulin produced from pooled
plasma (IVIG) is the major source for antibody therapy by
virtue of the diverse repertoire of immunoglobulin mole-
cules responsible for a wide spectrum of anti-bacterial and
anti-viral activities [2]. The pooled plasma of subjects that
had been naturally exposed to pathogens has been used
for the production of IVIG preparations containing spe-
cific antibodies for treatment of disease causing viruses,
including Cytomegalovirus, Hepatitis A, B and C, HIV,
Respiratory Syncytial Virus, Measles and Varicella Zoster
virus [1].
West Nile virus (WNV), a mosquito-transmitted flavivi-
rus, was first isolated from a febrile adult woman in the
West Nile District of Uganda in 1937 [3]. WNV is a single
stranded plus RNA virus, and a member of the Japanese
encephalitis antigenic complex of the genus Flavivirus,
family Flaviviridae [4,5]. Until 1999, West Nile Virus was
found in Africa, the Middle East, parts of Asia, Southern
Europe and Australia. It then suddenly emerged in New
York, rapidly spread throughout the United States and has
since caused considerably acute mortality and morbidity
[6]. The clinical manifestations of WNV in humans range
from asymptomatic seroconversion to fatal meningo-
encephalitis, with symptoms including cognitive dysfunc-
tion, muscle weakness and flaccid paralysis [7-10].
Depressed immunity, age and genetic factors [11,12] are
correlated with greater risk for neurological disease. Cur-
rently, there is no effective anti-viral therapy or human
vaccine for WNV infection.
Available evidence suggests that WNV might be more sus-
ceptible to antibody-mediated than cell-mediated immu-
nity. Indeed, passive transfer of specific antibodies (Ab) or
immunoglobulin has been shown to abort or modify
West Nile viral infections in animal models in a dose-
dependent manner [13-15]. WNV is endemic in Israel and
significant levels of anti-WNV Ab are found in commercial
preparations of IVIG prepared from the plasma of Israeli
donors (IVIG-IL). Anecdotal cases have suggested that the
presence of anti-WNV Ab in IVIG-IL assisted the recovery
of patients suffering from severe WNV infection [16,17].
We have previously shown that while IVIG-IL protected
mice against lethal doses of WNV, the low exposure to the
virus of US donors resulted in no effect of IVIG produced
from the plasma of US donors (IVIG-US) [13,18].
Recently, however, it has been shown that some IVIG
preparations produced in the USA during epidemic years
contained antibodies against WNV and thus, were protec-
tive in an animal model for WNV infection [19].
In order to enhance the therapeutic efficacy of IVIG
against WNV infection, OMRIX biopharmaceuticals firm
has developed a strategy for the selection of plasma units
from the 10% fraction of blood donors containing WNV
antibodies. Positive units were processed into pharmaceu-
tical grade WNV IVIG (WNIG). The potency of WNIG for
the neutralization of WNV NY99 strain was tested in vitro
by a cell neutralizing assay and in vivo, using a mouse
lethal model. WNIG was at least 5–10-fold more potent
than was regular IVIG-IL. Treatment with WNIG three or
four days after challenge was also efficacious. We con-
clude that blood from selected donors in WNV endemic
regions can improve the potency of IVIG and should be
developed for use in therapy and for prophylactic meas-
ures.
Methods
Mice
Female BALB/cOlaHsd mice (4–5 weeks old, 15–17 g at
study initiation; Harlan Laboratories, Israel) were used,
unless otherwise stated. Mice were maintained in isola-
tion cages throughout the study and fed and watered ad
libitum. The mouse experiments were approved and per-
formed according to the Kimron Veterinary Institute
guidelines for animal experimentation with arboviruses.
Cell Cultures
Vero cells (ATCC #CRL-1587) were grown in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with
10% fetal calf serum (FCS), 1% nonessential amino acids,
1.2% NaHCO3 and antibiotics. The cells were maintained
in a humidified atmosphere at 37°C containing 5% CO2
and were used for growing virus stocks and virus titration.
Virus stocks and virus titrations
WNV-NY99 (3rd passage in Vero cells of strain NY 385-
99) [20], was kindly provided to OMRIX biopharmaceuti-
cals by M.S. Diamond, Washington University, School of
Medicine, St. Louis, MO, USA. Virus plaque assays were
performed on Vero cells as previously described [21] and
virus titers were expressed as plaque-forming units (PFU)/
ml. A single virus stock containing 5 × 108 PFU/ml was
stored in aliquots at -70°C and was used in all studies.
Infection and challenge of mice
In all experiments (unless otherwise stated), 4–5 week old
mice were inoculated intraperitoneally (i.p.) with 0.2 ml
of coctail containing different quantities of stock virus per
mouse [18]. Lethal dose 50 (LD50) was calculated accord-
ing to the method of Reed and Muench [22].
Immunoglobulin (IVIG) preparations
OMRIX IVIG preparations (Omr-IgG-am™, OMRIX biop-
harmaceuticals, Israel) contain 5% protein, consisting
more than 99% IgG and a very small quantities of IgA andBMC Infectious Diseases 2009, 9:18 http://www.biomedcentral.com/1471-2334/9/18
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IgM. Three preparations (5% IVIG, produced by OMRIX)
were employed (Table 1): (a) High titer WNV-IVIG
(WNIG), Batch #K44G511. This product was prepared
during 2006 from Israeli plasma that was pre-screened by
ELISA for specific anti-WNV antibodies. About 10% of the
plasma units from the general blood donor population
had > 100 arbitrary units/ml (AU/ml) of anti-WNV anti-
bodies. These units were pooled for the production of
WNIG. (b) Commercial IVIG-IL batch #H23131, prepared
in 2003, from pooled plasma of Israeli blood donors. (c)
Commercial IVIG-US Batch #K30G370, prepared in 2006
from pooled plasma of US blood donors.
Antigen preparation
Inactivated WNV antigen was prepared by inactivation of
the stock virus with  -Propiolactone (0.001%final concen-
tration) [18,23].
Detection of anti-WNV antibodies by ELISA
a. ELISA for human antibodies
A quantitative ELISA was developed at OMRIX based on
the method described earlier [18]. To allow quantitative
measurements, a specific positive plasma sample was
assigned a value of 2000 AU/ml WNV antibodies. This
sample served as a calibration standard. The 1–10 AU/ml
range was found to display linear characteristics when the
log-transformation of concentration was plotted against
the observed optical density at 405 nm. Briefly, microtiter
plates were first coated with inactivated WNV antigen in
carbonate buffer, pH 9.6. The plates were blocked with
0.5% I-block (Tropix, Bedford, MA) and 10% goat serum.
Samples and controls were diluted in blocking buffer to fit
the standard curve range. Alkaline phosphatase-conju-
gated goat anti-human IgG (Sigma, Israel) was added as a
detector followed by pNPP substrate (Sigma, Israel). The
titer of each serum and control sample was calculated
from absorbance at 405 nm plotted against the log trans-
formation of calibrator concentration.
b. ELISA for mouse sera
An ELISA test was performed according to the method
described by Martin et al. [24], with slight modifications
[18]. Specific titers were expressed as the reciprocal of the
highest dilution giving a reading above the cut-off value
[25].
Plaque Reduction Neutralization Titer 50% (PRNT50)
The titer of neutralizing antibodies was determined using
a plaque reduction test based on the method described
earlier [18]. Briefly, samples were diluted by serial two-
fold dilutions (1:10 – 1:10,240) in DMEM, 2% FCS and
mixed with an equal volume of similar medium contain-
ing approx. 450 PFU/ml of WNV NY99. The mixtures were
incubated overnight at 4°C on a roller and the virus-anti-
body mixtures (400 μl) were then added to Vero cells pre-
seeded in 6-well plates at a concentration of 5 × 105 cells/
well and pre-grown overnight at 37°C, 5% CO2. After 60
minutes at 37°C in 5% CO2, the monolayers were over-
laid with 3 ml of Modified Eagle Medium (MEME) ×2 and
tragacanth (Sigma, Israel) containing 4% FCS and 2.4%
sodium bicarbonate. The cultures were incubated for an
additional 72 hours at 37°C in 5% CO2. The cells were
then fixed with ethanol, stained with fucsin, and plaques
were counted. PRNT50 values were expressed as the recip-
rocal of the highest dilution giving 50% reduction in
plaque numbers (WNU).
Treatment with Immunoglobulins
Following inoculation with WNV, mice received i.p. injec-
tions of different doses of IVIG-IL, IVIG-US or WNIG,
according to the specific experimental protocol. Treat-
ment doses ranged from 0.01 mg/mouse (about 0.6 mg/
kg) to 8 mg/mouse (about 470 mg/kg). The animals were
followed for mortality for at least 21 days.
WNIG Therapy of immunosuppressed mice
Seven to 8 weeks old mice received two subcutaneous
(s.c.) doses of dexamethasone (Sigma, Israel, 60 μg/
mouse each). The first dose was administered 2 hours
before inoculation with 5–10 PFU of WNV-NY99 and a
second dose was administered 1 day thereafter. Four
hours after inoculation with WNV, the animals were
treated i.p. with 1 mg or 0.2 mg/mouse of WNIG. The ani-
mals were followed for mortality for at least 21 days.
Statistics
Survival rates of the different groups were compared by
Fisher's exact test. Average days for death were compared
by Student's t-test.
Results
The protective effects of WNIG against lethal WNV 
infection
To study the relative protective efficacy of WNIG, as com-
pared to IVIG-IL or IVIG-US, mice were inoculated i.p.
Table 1: Anti-WNV antibodies in the IVIG preparations used for 
treatments
Titer by ELISA Titer by PRNT50
IVIG Preparation AU/ml AU/mg WNU/ml WNU/mg
WNIG 7608 152 9900 198
IVIG-IL 668 13 1032 21
IVIG-US 179 4 Not done
WNIG, high titer anti-WNV IVIG (from selected donors); IVIG-IL, 
IVIG preparation from the pooled plasma of Israeli donors; IVIG-US, 
IVIG preparation from the pooled plasma of US donors. AU, arbitrary 
units of anti-WNV antibodies per mouse (as assessed by ELISA, see 
Methods). WNU, the reciprocal of the highest dilution giving 50% 
reduction in a PRNT50 assay.BMC Infectious Diseases 2009, 9:18 http://www.biomedcentral.com/1471-2334/9/18
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with 10–20 LD50 (50–100 PFU) of WNV-NY99, followed
4 hours later by treatment with a single injection of 2, 0.5
or 0.1 mg of WNIG, IVIG-IL or IVIG-US. Treatment with 2
mg of WNIG/mouse or IVIG-IL was sufficient to confer
88–100% protection against 10–20 LD50  of the virus
(Table 2). As expected, IVIG-US showed lower protective
efficacy, with only 63% survival after treatment with 2.0
mg/mouse. The superiority of WNIG was clearly demon-
strated at a dose of 0.1 mg/mouse, where IVIG-IL con-
ferred only 44% protection, as compared to the 94%
protection attained with WNIG.
These results suggest that the protective efficacy of 0.1 mg
WNIG was similar to that obtained with 0.5 mg of IVIG-
IL, i.e. WNIG was at least 5-fold more efficacious. WNIG
at 0.1 mg showed a similar efficacy as IVIG-US at 2.0 mg,
i.e. WNIG was some 20-fold more efficacious. The superi-
ority of WNIG was also demonstrated by comparing the
levels of viremia in mice treated with IVIG-IL or WNIG
before inoculation with 50 PFU of WNV. Treatment with
0.1 mg IVIG-IL moderately decreased virus levels in the
blood of infected animals from an average of 3.4 to 2.0
log10 PFU/ml on day 2 and from 2.9 to 1.8 log10 PFU/ml
on day 3. No virus was detected in the blood of mice
treated with WNIG. About 6.2 log10  PFU/brain were
found on day 7 in brains of control-infected mice, while
no virus was detected in the brains of IVIG-IL- or WNIG-
treated mice (data not shown).
We further investigated the protective efficacy of lower
doses of WNIG and IVIG-IL. Groups of mice were infected
with 10 LD50 (50 PFU) of WNV and treated 4 hours later
with a single injection containing 0.05, 0.025 or 0.01 mg
of WNIG or 0.25 mg of IVIG-IL. As shown in Figure 1, a
5–10 fold increase in protective efficacy of WNIG over
IVIG-IL treatment was maintained, as revealed upon com-
paring treatment with 0.25 mg IVIG-IL to treatment with
0.05–0.025 mg WNIG. Mortality in these groups was
delayed compared to that of the control-infected mice. In
the untreated WNV-NY99 infected mice, all of the deaths
occurred by day 8. In the IVIG-IL (0.25 mg)-treated mice,
mortality was delayed and occurred between days 8–15. A
similar pattern of delayed mortality was obtained after
treatment with 0.05 or 0.025 mg of WNIG.
Detection of anti-WNV antibodies in surviving mice
De-novo synthesis of anti-WNV antibodies in WNIG-
treated, surviving mice was tested 21, 40 and 60 days after
challenge and treatment. Animals were challenged with
10 LD50/mouse and 4 h later, were treated with WNIG or
IVIG-IL (0.1–0.5 mg/mouse). Pooled serum samples were
collected from surviving mice on days 21, 40 and 60 after
treatment and antibody titers were assessed by ELISA. The
surviving animals presented high levels of anti-WNV anti-
body titers ranging from 1:8,000–1:16,000. The high tit-
ers of anti-WNV antibodies were maintained for at least
60 days.
Therapeutic efficacy of WNIG
In the mouse model, active encephalitis can be detected 3
days after challenge with WNV [18,32]. To study the ther-
apeutic efficacy of WNIG, mice were injected with 10 LD50
of WNV, and treated with 2 mg WNIG or IVIG-IL on days
2 and 4 or 3 and 5 after infection. As shown in Figure 2,
injection of 2 mg of WNIG on days 2 and 4 after infection
protected 100% of the animals, as compared with the
75% protection observed in mice receiving IVIG-IL. Treat-
ment with WNIG on days 3 and 5 significantly delayed
mortality of the infected mice. In this group, 62% of the
animals survived for 17 days. The average period of death
in the WNIG group treated on days 3 and 5 was 12.5 days
(SD = 5.7), while the average period of death in the IVIG-
IL group treated 3 and 5 days after infection and in
untreated mice were 7.1 days (SD = 1.1) and 6.6 days (SD
= 0.5), respectively (p = 0.032 for the WNIG group as
compared to the IVIG-IL group; p = 0.048 for the WNIG
group as compared to untreated group).
To assess the therapeutic effect offered by a higher dose of
WNIG, a single dose of 8 mg/mouse was given on days 3,
Table 2: Protective efficacy of WNIG, IVIG-IL and IVIG-US in mice infected with 10–20 LD50 of WNV NY99
Treatment (mg/mouse) Specific Ab dosea Percent survival (live/treated)
No treatment 0 7 (1/14)b
WNIG (0.1 mg) 15 94 (15/16)c
IVIG-IL (0.1 mg) 1.3 44 (7/16)
WNIG (0.5 mg) 76 100 (16/16)
IVIG-IL (0.5 mg) 7 87 (14/16)
WNIG (2.0 mg) 304 100 (8/8)
IVIG-IL (2.0 mg) 27 88 (7/8)
IVIG-US (2.0 mg) 7 63 (5/8)
Groups of 4–5 week-old BALB/c mice were treated i.p. with different amounts of WNIG or IVIG-IL, 4 h after injection of 10–20 LD50 of West Nile 
virus. Animals were observed daily for mortality for 21 days. aArbitrary units of anti-WNV antibodies per mouse (as assessed by ELISA, see 
Methods). bp < 0.039, as compared to all treatment groups. cp = 0.006, as compared to the IVIG-IL (0.1 mg) group.BMC Infectious Diseases 2009, 9:18 http://www.biomedcentral.com/1471-2334/9/18
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4, or 5 after infection. This dosage protected all of the ani-
mals when administered 3 days after infection (Table 3).
When given 4 days after infection, the survival rate was
63% as compared to the 25% survival rate measured in
the untreated control group. Treatment on day 5 after
infection was not effective, suggesting that, at this point,
the damage cause by the virus was irreversible.
WNIG therapy of immunosuppressed mice
Resistance to viral infection can be modified by treatment
with dexamethasone [21,26]. Seven to 8 weeks old mice
were chosen for this experiment, since we found that such
mice are more resistant to low dose WNV infection than
are younger animals (data not shown). Mice were injected
s.c with two doses of 60 μg/mouse of dexamethasone. The
first dose was administered 2 h before infection with 5–10
PFU of WNV NY-99 strain. A second dose was adminis-
tered 1 day later.
Dexamethasone treatment increased the susceptibility of
adult mice to WNV, thereby lowering the survival rate
from 58% to less than 19%. Treatment of dexamethasone-
immunosuppressed mice with 0.2 or 1.0 mg WNIG 4 h
after viral infection resulted in 100% survival (Table 4).
Discussion
Antibody-based therapy against viral and bacterial infec-
tions has been successfully practiced since the end of the
19th century [27]. Since the emergence of West Nile virus
(WNV) as an important pathogen in a number of regions,
including the continental USA, the potential use of spe-
cific antibodies for protection and treatment of infections
associated with WNV has been studied in several animal
models, including different mouse strains and Syrian
golden hamsters [13,18,28-30].
We have previously shown, using a mouse model, that
commercial preparations of IVIG from normal Israeli
blood donors imparts protection to mice against viral
infection. The emergence of WNV in many regions of the
continental USA after 1999 has allowed others to confirm
the efficacy in animal models, of IVIG produced from spe-
cific US regions [19]. Using a different approach, human-
ized monoclonal antibodies against specific epitopes in
the viral envelope showing high in-vivo  potency were
developed [31]. Despite these successes it is still easier to
develop a new formulation derived from a known phar-
maceutical product with an excellent safety profile, such
as IVIG [1]. Therefore, the use of IVIG with high WNV
antibody levels is considered a leading approach for treat-
ment of WNV infection. Although the potential use of
IVIG from regions endemic for WNV has been was
reported, a serious limiting factor in applying this concept
is the relatively low levels of specific antibodies and very
high batch-to-batch variance in WNV antibody levels,
especially in IVIGs produced in countries such as the USA
where the exposure of donors to WNV is limited and not
homogenous [19]. Even in hyper-endemic regions such as
Israel, only a fraction of the population has a history of
exposure to WNV [17].
Our finding that only 8–10% of the plasma units from the
normal donor population contributed almost all of the
anti-WNV antibodies to the plasma pools allowed the
development of a highly effective WNV treatment option
The IVIG produced from positive WNV antibody-contain-
ing plasma units selected by ELISA, termed WNIG,
showed promising potential in a cell neutralizing assay,
with about 10-fold higher anti-WNV antibody levels
being detected, as compared to regular IVIG-IL (9900
compared to 1032 WNU, by PRNT50, and 7608 compared
to 668 AU, by ELISA, respectively). Indeed, good correla-
tion was shown between the ELISA and PRNT50 results.
Dose-dependent protection by WNIG Figure 1
Dose-dependent protection by WNIG. Groups of 5-
week old BALB/c mice were treated i.p. with IVIG-IL (0.5 or 
0.25 mg/mouse) or with WNIG (0.01, 0.05, or 0.025 mg/
mouse) 4 h after infection with 10 LD50 of WNV NY99. Mice 
were observed for mortality for 21 days. One group of 
infected mice received no treatment (control).
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Therapeutic efficacy of WNIG Figure 2
Therapeutic efficacy of WNIG. Groups of 5-week old 
BALB/c mice were treated i.p. with 2 mg/mouse IVIG-IL or 
WNIG on days 2 and 4, or days 3 and 5 after infection with 
10 LD50 of West Nile virus. Mice were observed for mortal-
ity for 21 days. One group of infected mice received no 
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Tests in mice confirmed the in vitro analysis by showing 5–
10 fold enhancement (per g of total IgG) of efficacy when
compared to regular IVIG-IL produced from Israeli donors
and at least one log increase compared to IVIG-US pro-
duced from US donors.
When considering WNIG as a practical clinical option,
treatment of patients with active encephalitis should be
evaluated. The penetration of antibodies across the blood
brain barrier (BBB) is highly inefficient but it is speculated
that during active disease, the BBB becomes partially per-
meable thereby allowing penetration of significant quan-
tities of antibodies to the infected site. As the level of
antibodies in the serum is directly correlated to antibody
levels in the brain, the goal of any treatment is to supply
as many antibodies as possible, especially when trying to
combat active disease. The protective effects of IVIG and
monoclonal antibodies against infection already estab-
lished in the brain was previously shown in animal mod-
els [15,18,28]. In human, intravenous immunoglobulin
treatment was reported to be associated with improve-
ment and elimination of the signs and symptoms of WNV
infection [16,17]. Our results support the superiority of
WNIG over regular IVIG-IL when given to mice even 3 or
4 days after infection, at the point where WNV had already
established infection in the brain [18,32]. Augmenting
the level of antibodies against WNV may thus prove to be
an important treatment strategy for infection, particularly
for the elderly and those with immune systems deficien-
cies [33]. Immuno-compromised subjects represent a
major target population for passive antibody treatment or
prophylaxis against WNV infection. Concomitant admin-
istration of dexamethasone and pathogens leads to wide-
spread suppression of the innate immune response [26],
enhanced viral replication and mortality [21]. It was
shown that a broad range, non-specific immunosuppres-
sion increases the sensitivity of golden hamsters to WNV
infection [34]. Engle and Diamond [28] showed that anti-
bodies can only partially restore the protection against
WNV infection thus suggesting that an efficient anti-viral
response requires the combined activities of the innate
and specific immune systems. However, we show here
that WNIG alone was highly effective even when co-
administered with the aggressive immuno-suppression
agent, dexamethasone, which affects the innate immunity
[26]. Treatment with WNIG offered complete protection
to mice injected with dexamethasone, while the mortality
among control infected mice injected with dexametha-
sone exceeded 80%.
When considering the practical application of passive
immunotherapy to fight WNV infection, the total quantity
of specific antibodies administered is limited by the max-
imum quantity of IVIG allowed for IV infusion (up to 2 g/
kg). The use of WNIG will allow the administration of 5–
10 times more specific antibodies, as compared to regular
IVIG-IL, thus providing significantly enhanced therapeu-
tic potential.
Conclusion
The protective efficacy of WNIG, when administered 3
and 4 days after infection, suggests that the use of IVIG
containing a high titer anti-WNV antibodies offers great
potential for controlling active infection, even in the CNS.
The possibility of exploiting the augmented levels of spe-
cific antibodies in a small fraction of the population by
selection of plasma units before processed into IVIG will
allow for the use of acceptable doses of IgG in patients,
thereby increasing their chances for survival or lowering
the risks of immediate and/or long term adverse effects.
Table 3: Protective efficacy of WNIG in mice infected with 10 LD50 of WNV.
Treatment day (after challenge) Treatment dose (mg/mouse) Percent survival (live/treated)
No treatment - 25 (2/8)
Day 0 2 100 (8/8)
Day 0 8 100 (8/8)
Day 3 8 100 (8/8)
Day 4 8 63 (5/8)
Day 5 8 38 (3/8)
Groups of 4–5 week-old BALB/c mice were treated i.p. with WNIG (2 or 8 mg/mouse), 4 h, or on days 3, 4, or 5 after injection of 10–20 LD50 of 
WNV. Mice were observed daily for mortality for 21 days.
Table 4: Therapy of immunosuppressed mice by WNIG.
Treatment group Survival % (live/treated)
WNV control 58 (7/12)
Dexamethasone 19 (3/16)a
Dex + WNIG (1.0 mg/mouse) 100 (17/17)
Dex + WNIG (0.2 mg/mouse) 100 (16/16)
Group of 7–8 week-old BALB/c mice received two s.c. injection of 60 
μg/mouse, dexamethasone (Dex), 2 hours before, and one day after 
infection with WNV. Mice were treated i.p. with WNIG (1.0 or 0.2 
mg/mouse), 4 h after infection with 5–10 PFU of WNV. Mice were 
observed daily for mortality for 21 days. No mortality was observed 
in no-infected dexamethasone-treated mice.
ap < 0.001, as compared to the WNIG (0.2–1.0 mg) group.BMC Infectious Diseases 2009, 9:18 http://www.biomedcentral.com/1471-2334/9/18
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Abbreviations
Ab: antibodies; DMEM: Dulbecco's modified eagle
medium; FCS: fetal calf serum; i.p.: intraperitoneal; IVIG:
intravenous immunoglobulin; IVIG-IL: IVIG prepared
from plasma of Israeli blood donors; IVIG-US: IVIG pre-
pared from plasma of US blood donors; LD50: lethal dose
50%; MEM: modified eagle medium; PFU: plaque form-
ing units; s.c.: subcutaneous; WNIG: IVIG prepared from
plasma of Israeli blood donors with anti-WNV antibodies;
WNV: West Nile virus.
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